Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: lexi2004 who wrote (59168)	10/9/2007 8:10:56 PM
From: Findit	Read Replies (1) \| Respond to of 59879

Lexi thanks much for the input. You mentioned that the prior high had more volume. That high had FDA meeting anticipation and buyout offer in the .70's. This time we only have analyst thinking the FDA did not get all the facts at the last meeting and are now better informed and that chances of approval have risen. This is getting the pps to move. Prior to any decision on the approval of oRBEC, I plan to lighten up between here and .80 (if I get so lucky). I will hold some just in case the approval comes. I expect a huge move with approval. Without approval, they still have Europe to market to, so the price still could stay above my entry level. With Europe only, they would best look for a suitor for a buyout. Let me know if you decide to reenter. Thx. Jim